Article

Personalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancer

2022-12-13

Abstract excerpt

Immune checkpoint inhibitors (ICIs) or combined with chemotherapy have shown outstanding efficacy in treatment of advanced non-small cell lung cancer (NSCLC). However, efficient biomarkers for monitoring response to first-line ICIs ± chemotherapy remain unclear. In our study, 16 tumor tissues and 46 matched peripheral blood samples at baseline and during treatment from 19 locally advanced or metastatic NSCLC patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f5aa4e04-4f0a-52d7-a8dd-a81bc8cc1714
DOI: 10.21203/rs.3.rs-2357859/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Personalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancerDOI 10.21203/rs.3.rs-2357859/v1Read

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.Semantic proximity Read

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.Semantic proximity Read

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.Semantic proximity Read

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Semantic proximity Read